Advertisement


Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study

2024 ASCO Annual Meeting

Advertisement

Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
YoungPEARL study is a prospective randomized phase 2 study to compare palbociclib plus exemestane plus GnRH agonist versus capecitabine for premenopausal HR-positive HER2-negative metastatic breast cancers. Actually, this clinical trial was published and presented in 2019. According to that trial research, palbociclib plus exemestane plus GnRH antagonist showed a superior PFS compared to the capecitabine. Their median PFS was 20.1 months versus capecitabine, 14.4 months. This kind of real big research contributed to expansion of palbociclib plus AI label to include premenopausal population. So now, here we reported updated overall survival research. Data cutoff is February 29th, 2024 with median follow-up duration of 54 months. So we follow up the updated PFS research to show the consistent superior PFS showed in palbociclib arm. Median PFS was 19.5 months versus 14 months of PFS shown in capecitabine arm. Hazard ratio in people was strongly enough to consider it's a big impact in terms of PFS. And now, we show the overall survival research. There is no big difference between the two arm. Palbociclib arm showed the 54.7 months of PFS, and then capecitabine arm showed a remarkable PFS of 57.8 months. They did not show any difference, but it's 54 months of longer follow-up duration. Palbociclib arm showed a pretty consistent, longer overall survival of 54.8 months. So it's a really... Extended overall survival was shown in palbociclib arm. But palbociclib superior PFS did not lead to the overall survival benefit compare capecitabine arm. But capecitabine arm showed... Multivariate analysis showed the post-treatment CDK4/6 inhibitor was identified as a independent favorable factor for overall survival with statistical significance. So maybe post CDK inhibitor treatment contributed to extended overall survival in palbociclib arm.

Related Videos

Breast Cancer

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Gynecologic Cancers

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).

Leukemia
Lymphoma

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Advertisement

Advertisement




Advertisement